Stay updated with breaking news from Ann Hematol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The National Institute for Health and Care Excellence has published its Final Draft Guidance recommending the use of ruxolitinib as treatment for eligible patients in England and Wales with polycythemia vera that is resistant or intolerant to hydroxycarbamide/hydroxyurea.
BURLINGTON, Mass., August 04, 2023--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the publication of a cost-effectiveness analysis of ropeginterferon alfa-2b-njft (marketed as BESREMi®) in the Journal of Comparative Effectiveness Research. The analysis, titled "Cost-Effectiven
Analysis published in the Journal of Comparative Effectiveness Research shows ropeginterferon alfa-2b-njft provided a cost-effective benefit in quality-adjusted life years compared to a commonly used treatment pathwayBURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia C...
Neutropenic sepsis is a potentially life-threatening condition when a patient with low neutrophil counts develops an infection that spirals out of control if not treated urgently and is usually seen in cancer patients on chemotherapy.
Achieving MRD flow cytometry negativity is crucial in monitoring and predicting survival outcomes.